NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients

CompletedN/A

Sponsor: ARCAGY/ GINECO GROUP

Conditions: Relapsed Ovarian Cancers Patients

Interventions: Olaparib

Countries: France

This is a national, multi center, retrospective observational cohort study that will be carried out by reviewing the medical records of patients with relapsed epithelial ovarian, fallopian tube, or peritoneal cancer treated with olaparib following response to platinum-based chemotherapy.

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients must be female ≥18 years of age
* Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer that were treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy
* Patients can be either alive or deceased at the time of medical record abstraction
* Patients should not have any objection that anonymized data will be collected and subjected to automated processing.

Exclusion Criteria:

* Patient that were given olaparib within a clinical trial

Locations (28)

Angers, France
Avignon, France
Besançon, France
Bordeaux, France
Bordeaux, France
Brest, France
Brest, France
Clermont-Ferrand, France
Dijon, France
Grenoble, France
Levallois-Perret, France
Lyon, France
Montpellier, France
Nancy, France
Nantes, France
Nice, France
Orléans, France
Paris, France
Paris, France
Reims, France
Rennes, France
Saint-Brieuc, France
Saint-Herblain, France
Saint-Nazaire, France
Saint-Priest-en-Jarez, France
Strasbourg, France
Vandœuvre-lès-Nancy, France
Villejuif, France